

The Role of Propylthiouracil in the Management of Graves' Disease in Adults

April 18, 2009

MEETING AGENDA

8:00 am – 8:30 am	Continental Breakfast
8:30 am – 8:45 am	Introductions and Welcome Kenneth Burman, MD, ATA President, Washington Hospital Center Mary Parks, MD, FDA Donald Mattison, MD, NICHHD, NIH; Anne Zajicek, MD, NICHHD, NIH David S. Cooper, MD, Meeting Chair, Johns Hopkins University
8:45 am – 9:30 am	Antithyroid Drugs: Pharmacology, Clinical Use and Adverse Events in Adults David S. Cooper, MD, Johns Hopkins University
9:30 am – 10:00 am	Management of Thyrotoxicosis in Pregnancy Susan Mandel, MD, MPH, University of Pennsylvania
10:00 am – 10:30 am	Antithyroid Drugs: Approval History and Labeling Naomi Lowy, MD, FDA
10:30 am – 10:45 am	Break
10:45 am – 11:15 am	Frequency of PTU and Methimazole Use: Outpatient Prescription Utilization Data Laura Governale, PharmD, MBA, FDA
11:15 am – 11:45 am	PTU and Methimazole: Severe Liver Injury Joslyn Swann, PharmD, FDA
11:45 am – 12:00 pm	Discussion
12:00 pm – 1:00 pm	Lunch
1:00 pm – 1:45 pm	Methimazole Embryopathy and Possible Mechanisms of Teratogenesis Miyun Tsai-Turton, PhD, FDA
1:45 pm – 2:30 pm	Drug-Induced Liver Failure: Mechanisms John Senior, MD, FDA
2:15 pm – 2:45 pm	Break
2:45 pm – 3:00 pm	Drug-Induced Liver Failure: Epidemiology and Role of Monitoring Mark Avigan, MD, FDA
3:00 pm – 3:30 pm	Discussion
3:30 pm	Adjournment